China Chinese Patent Medicine Industry Report, 2010
  • Dec/2010
  • Hard Copy
  • USD $1,500
  • Pages:63
  • Single User License
    (PDF Unprintable)       
  • USD $1,400
  • Code: ZYM018
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,100
  • Hard Copy + Single User License
  • USD $1,700
      
China is the birthplace of Chinese Patent Medicine, and a major producer and consumer of Chinese patent medicine in the world. Driven by both policy incentives and market demand, Chinese patent medicine has developed well in China. From 2006 to 2009, China’s industrial output value and sales revenue of Chinese patent medicine grew at annual rates of 13.9% and 12.7% respectively. The terminal sales revenue of Chinese patent medicine has always accounted for about 30% of the total pharmaceutical revenue of China since 2006. As of August 2010, there had been 1,522 Chinese patent medicine manufacturers in China, including over 30 listed companies, such as Tasly, Tongrentang and Yunnan Baiyao; there had been over 10,000 kinds of Chinese patent medicine, such as Tasly’s Compound Danshen Dripping Pill (Fu Fang Dan Shen Di Wan), Tongrentang’s Bolus of Six Drugs Including Rehmannia (Liu Wei Di Huang Wan) and Bolus of Black-bone Chicken (Wu Ji Bai Feng Wan); there had been over 40 dosage forms, such as traditional bolus, ointment, powder and pellet as well as modern capsule, tablet and spray.

Industrial Output Value and Prime Operating Income of Chinese Patent Medicine in China, 2006-2009(RMB bn)
 2010122005.gif
Source: ResearchInChina; National Bureau of Statistics of China

As China’s Chinese patent medicine has gained increasing international recognition and high profit (generally, the operating profit margin is above 70%), and the chemical and pharmaceutical industry has encountered development bottlenecks, global pharmaceutical giants and related institutions have marched into China’s Chinese patent medicine-related fields through joint venture, sole proprietorship or other forms. For example, Novartis and Kunming Pharmaceutical signed a General Agreement on Patent Development Permit for the R & D and production of artemether raw materials, U.S. National Institutes of Health (NIH) (the world's largest medical research institute and research fund management institution) and Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited signed a cooperative agreement on the research of anti-virus mechanism of Baiyunshan Radix Isatidis Granule.

Due to the particularity of Chinese patent medicine market, manufacturers generally can only set foot in some market segments instead of all application fields of Chinese patent medicine. Moreover, as there are a lot of manufacturers engaged in Chinese patent medicine, the competition among them is intense, and the market concentration is low even in market segments. For example, in the field of Chinese patent medicine for cardiovascular and cerebrovascular diseases, top 4 brands accounted for 12.4%, 14.6% and 17.1% of the total market respectively during 2007 to 2009, while top 10 brands held 24.1%, 27.8% and 31.2% of the total market respectively during 2007 to 2009. However, the market concentration of Chinese patent medicine for cardiovascular and cerebrovascular diseases is showing an upward trend in China.

The report analyzes the domestic & global operating environment, current development, supply & demand, competition pattern, import & export and market segments of China’s Chinese patent medicine industry. It also studies the operation and development prospect of 10 listed Chinese patent medicine enterprises, including Tasly, Kanion Pharmaceutical, Yunnan Baiyao, Tibet Cheezheng Tibetan Medicine, Tibet Rhodiola Pharmaceutical, Kunming Pharmaceutical, CONBA, Tongrentang and Guilin Sanjin.
1. Overview of Chinese Patent Medicine
1.1 Definition and Classification
1.2 Comparison among Chinese Patent Medicine, Herbal Medicine and Natural Medicine
1.3 Industry Chain

2. Market Operating Environment for China’s Chinese Patent Medicine
2.1 Global Environment
2.1.1 Polices
2.1.2 Market Status
2.1.3 Development Trend
2.2 Domestic Environment
2.2.1 Polices
2.2.2 Operation of TCM Industry

3. Overview of China’s Chinese Patent Medicine Market
3.1 Status Quo
3.2 Supply and Demand
3.2.1 Supply
3.2.2 Demand
3.3 Competition
3.4 Import & Export
3.4.1 Export
3.4.2 Import
3.5 Development Prospect and Trend
3.5.1 International Market
3.5.2 Domestic Market
3.5.3 Influence of Raw Materials

4. Chinese Patent Medicine Market Segments in China
4.1 Cardiovascular and Cerebrovascular
4.1.1 Market Scale
4.2 Anti-tumor
4.3 Respiratory System

5. Major Chinese Patent Medicine Manufacturers in China
5.1 Tasly
5.1.1 Profile
5.1.2 Operation
5.1.3 Development Prospect and Trend
5.2 Kanion Pharmaceutical
5.2.1 Profile
5.2.2 Operation
5.2.3 Development Prospect and Advantages
5.3 Yunnan Baiyao
5.3.1 Profile
5.3.2 Operation
5.3.3 Development Prospect and Advantages
5.4 Pien Tze Huang
5.4.1 Profile
5.4.2 Operation
5.4.3 Development Prospect and Advantages
5.5 Tibet Cheezheng Tibetan Medicine
5.5.1 Profile
5.5.2 Operation
5.5.3 Development Prospect and Advantages
5.6 Tibet Rhodiola Pharmaceutical
5.6.1 Profile
5.6.2 Operation
5.6.3 Development Prospect and Advantages
5.7 Kunming Pharmaceutical
5.7.1 Profile
5.7.2 Operation
5.7.3 Development Prospect and Advantages
5.8 CONBA
5.8.1 Profile
5.8.2 Operation
5.8.3 Development Prospect and Advantages
5.9 Tongrentang
5.9.1 Profile
5.9.2 Operation
5.9.3 Development Prospect and Advantages
5.10 Guilin Sanjin
5.10.1 Profile
5.10.2 Operation
5.10.3 Development Prospect and Advantages
Chinese Patent Medicine Industry Chain
Distribution of global Herbal Medicine Market, 1999-2005
Market Shares of Herbal Medicine Enterprises in the World, 2005
Cases of Foreign Enterprises Entering the Field of Chinese Herbal Medicine  
National Policies Related with Chinese Patent Medicine
Total Output Value of Traditional Chinese Medicine Industry and by Sub-sector, 2006-2009
Industrial Output Value and Sales Revenue of Chinese Patent Medicine in China, 2006-2009
Number of Chinese Patent Medicine Enterprises in China, 2006-Aug. 2010
Chinese Patent Medicines Included in the Catalog of Essential Medicines and National Medical Insurance-covered Medicines of China by Category, 2009
Output and Growth Rate of Chinese Patent Medicine in China, 2006-2009
Output of Chinese Patent Medicine (by Region) in China, 2009
Chinese Patent Medicine Terminal Sales Revenue and Its Proportion in Pharmaceutical Market in China, 2005-2009
Product Structure of Chinese Patent Medicine Market (by Purpose and Effectiveness) in China, 2009
China’s Export Volume and Value of Chinese Patent Medicine, 2006-H1 2010        
Export Destinations of China’s Chinese Patent Medicine, H1 2010
China’s Export Volume and Value of Chinese Patent Medicine by Product, H1 2010        
Top 10 Provinces by Export of Chinese Patent Medicine, H1 2010
China’s Import Volume and Value of Chinese Patent Medicine, 2007-H1 2010      
Countries and Regions Where China Imported Chinese Patent Medicine from, H1 2010
Major Regions Where China Imported Chinese Patent Medicine from, H1 2010
Gross Margin of Major Chinese Patent Medicine Enterprises in China, 2007-H1 2010
Monthly Prices of Several Chinese Herbal Medicines in China, 2010
Top 10 Brands of Chinese Patent Medicine for Cardio-cerebral-vascular Diseases in China, 2007-2009
Proportion of Chemical Pharmaceutical to Chinese Patent Medicine in Chinese Anti-tumor Market, 2009
Top 10 Brands of Chinese Patent Medicine for Anti-tumor and Immune Regulation in China, 2009
Market Scale and Growth Rate of Chinese Patent Medicine (Granule) for Throat and Heat Expelling in China, 2006-2009
Top 10 Brands of Chinese Patent Medicine for Throat in China, 2008
Top 10 Brands of Chinese Patent Medicine (Granule) for Heat Expelling in China, 2008
Operating Income and Total Profit of Tasly, 2007-H1 2010
Operating Income of Tasly (by Industry), H1 2010
Operating Income of Tasly (by Region), H1 2010
Modern Traditional Chinese Medicine Industry Chain of Tasly
Operating Income and Total Profit of Kanion Pharmaceutical, 2007-H1 2010
Operating Income and Operating Profit Margin of Kanion Pharmaceutical (by Industry or Product), 2009-H1 2010
Operating Income and Total Profit of Yunnan Baiyao, 2007-H1 2010
Operating Income and Operating Profit Margin of Yunnan Baiyao (by Industry or Product), 2009-H1 2010
Operating Income of Yunnan Baiyao (by Region), 2009-H1 2010
Operating Income and Total Profit of Pien Tze Huang, 2007-H1 2010
Operating Income and Operating Profit Margin of Pien Tze Huang by Product, 2007-H1 2010
Operating Income of Pien Tze Huang (by Region), 2009-H1 2010
Operating Income and Total Profit of Tibet Cheezheng Tibetan Medicine, 2007-H1 2010
Operating Income and Operating Profit Margin of Tibet Cheezheng Tibetan Medicine (by Product), 2007-H1 2010
Operating Income of Tibet Cheezheng Tibetan Medicine (by Region), 2009-H1 2010
Operating Income and Total Profit of Tibet Rhodiola Pharmaceutical, 2007-H1 2010
Operating Income and Operating Profit Margin of Tibet Rhodiola Pharmaceutical (by Product), 2009-H1 2010
Operating Income and Total Profit of Kunming Pharmaceutical, 2007-H1 2010
Operating Income and Operating Profit Margin of Natural Medicine of Kunming Pharmaceutical, 2007-H1 2010
Operating Income of Kunming Pharmaceutical (by Region), 2009-H1 2010
Operating Income and Total Profit of CONBA, 2007-H1 2010
Operating Income and Operating Profit Margin of CONBA's Modern Herbal Medicine, 2007-H1 2010
Operating Income of CONBA (by Region), 2009-H1 2010
Operating Income and Total Profit of Tongrentang, 2007-H1 2010
Operating Income and Net Profit of Subsidiaries of Tongrentang, 2009
Operating Income of Tongrentang (by Region), 2009-2010
Operating Income and Total Profit of Guilin Sanjin, 2007-H1 2010
Operating Income and Operating Profit Margin of Guilin Sanjin (by Product), 2009-H1 2010
Operating Income of Guilin Sanjin (by Region), 2009-H1 2010

China Dental Industry Report, 2014-2018

Oral industry refers to the medical industry chain on the basis of oral medical consumption, mainly covering oral medical apparatus (equipment and consumables) and oral medical services. As reform of ...

China Medical Monitor Industry Report, 2014-2017

With advancement of medical reform, improvement of spending power, and enhancement of health care consciousness, China’s medical monitor industry is gradually expanding. During 2007-2013, the market s...

China Independent Clinical Laboratory Industry Report, 2014-2017

The independent clinical laboratory industry starts relatively late in China, featuring a limited overall size but high-speed development. In 2013 the independent clinical laboratory market size there...

China Interventional Cardiovascular Device Industry Report,2014-2017

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing ye...

China PTCA Balloon Market Investment Report, 2014-2016

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. There...

China Orthopedic Instrument Industry Report, 2014-2017

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale ...

China Hospital Development and Investment Report, 2014-2017

China hospital industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6...

China Diagnostic Reagent Industry Report, 2013-2016

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...

China Hemodialysis Equipment Import and Export Report, 2013-2016

Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...

Global and China Hemodialysis Industry Report, 2013-2016

Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure. In 2013, the global number of patient...

China Portable Medical Equipment Industry Report, 2013-2016

With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...

China Medical Informatization Industry Report,2013-2016

Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...

China Aged Care Industry Report, 2013-2016

Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...

China Pharmaceutical Equipment Industry Report, 2013-2016

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...

China Dental Industry Report, 2013-2016

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...

China Medical Monitor Industry Report, 2013-2015

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...

China Diagnostic Reagent Industry Report, 2013-2015

Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统